BioSpace News Archive

Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the promotion of Crystal Muilenburg from VP, Corporate Communications & PR to Chief Marketing Officer effective today.

Maven, the world’s largest virtual clinic for women’s and family health, today announced the expansion of its award-winning fertility program with the launch of MavenRx.

Canadian Medical Association members in Alberta have voted Dr. Alika Lafontaine as a nominee for CMA president in 2022–23.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced the exercise of 712,500 warrants from its June 2020 financing for net proceeds to the company of $1,425,000.

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced the closing of its previously announced private placement of 10,921,502 ordinary shares and warrants to purchase up to 5,460,751 ordinary shares, at a purchase price of $3.6625 per share and associated warrant, that was priced “at-the-market” under Nasdaq rules and resulted in gross proceeds of approximately $40.0 million

Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of inflammatory lung diseases and cancer, today announced that Chimerix, Inc. (NASDAQ:CMRX)

Children’s Minnesota announced that it received the Centers for Medicare and Medicaid Services certification of its Heart Failure and Heart Transplant program.

The Alzheimer’s Drug Discovery Foundation, a leading nonprofit solely focused on accelerating the development of drugs for Alzheimer’s disease and related dementias, announces that Christopher Johnson, CEO of Rackson Restaurants, has been appointed as Co-Chair of the ADDF’s Board of Overseers.

Atrion Corporation announced that its Board of Directors declared a quarterly dividend of $1.75 per share on its outstanding shares of Common Stock.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, announced that it will host a Town Hall at 1 P.M., Eastern Time on Thursday, March 18, 2021.